Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jan 21;22(3):1139-59.
doi: 10.3748/wjg.v22.i3.1139.

Advanced gastric cancer: What we know and what we still have to learn

Federico Coccolini  1 , Giulia Montori  1 , Marco Ceresoli  1 , Simona Cima  1 , Maria Carla Valli  1 , Gabriela E Nita  1 , Arianna Heyer  1 , Fausto Catena  1 , Luca Ansaloni  1
Affiliations
Review

Advanced gastric cancer: What we know and what we still have to learn

Federico Coccolini et al. World J Gastroenterol. .

Abstract

Gastric cancer is a common neoplastic disease and, more precisely, is the third leading cause of cancer death in the world, with differences amongst geographic areas. The definition of advanced gastric cancer is still debated. Different stadiating systems lead to slightly different stadiation of the disease, thus leading to variations between the single countries in the treatment and outcomes. In the present review all the possibilities of treatment for advanced gastric cancer have been analyzed. Surgery, the cornerstone of treatment for advanced gastric cancer, is analyzed first, followed by an investigation of the different forms and drugs of chemotherapy and radiotherapy. New frontiers in treatment suggest the growing consideration for intraperitoneal administration of chemotherapeutics and combination of traditional drugs with new ones. Moreover, the necessity to prevent the relapse of the disease leads to the consideration of administering intraperitoneal chemotherapy earlier in the therapeutical algorithm.

Keywords: Advanced gastric cancer; Chemotherapy; Definition; Hypertermic intraperitoneal chemotherapy; Intraperitoneal; Surgery.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Overall 1-year (A), 2-year (B), 3-year (C) or 5-year (D) survival in patients undergone to CC0-CC1 procedure[62].
Figure 2
Figure 2
One-year (A) or 3-year (B) survival compared between CC0 and CC1 cytoreduction[62].
Figure 3
Figure 3
Overall 1-year (A), 2-year (B) or 3-year (C) mortality in intraperitoneal chemotherapy[102].
Figure 4
Figure 4
Two-year (A) or three-year (B) mortality in patients with locoregional nodal metastasis[102].
Figure 5
Figure 5
One-year (A) or 2-year (B) mortality in patients with serosal infilatration[102].
Figure 6
Figure 6
Overall (A) or peritoneal (B) recurrence in patients treated with intraperitoneal chemotherapy[102].
See this image and copyright information in PMC

References

    1. American Cancer Society. Cancer Facts and Figures 2013. Atlanta: American Cancer Society; 2013. Available from: http://www.cancer.org/research/cancerfactsfigures/cancerfactsfigures/can....
    1. Jung KW, Won YJ, Kong HJ, Oh CM, Seo HG, Lee JS. Prediction of cancer incidence and mortality in Korea, 2013. Cancer Res Treat. 2013;45:15–21. - PMC - PubMed
    1. World Health Organization. GLOBOCAN 2012: Estimated Cancer Incidence. Mortality and Prevalence: Worldwide; 2012.
    1. Karimi P, Islami F, Anandasabapathy S, Freedman ND, Kamangar F. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomarkers Prev. 2014;23:700–713. - PMC - PubMed
    1. Bauer K, Schroeder M, Porzsolt F, Henne-Bruns D. Comparison of international guidelines on the accompanying therapy for advanced gastric cancer: reasons for the differences. J Gastric Cancer. 2015;15:10–18. - PMC - PubMed

MeSH terms

Substances